First patients in the U.S. treated with OssDsign Catalyst
Uppsala, October 7, 2021, OssDsign AB (publ) today announces that the first patients in the U.S. have been treated with OssDsign Catalyst – a synthetic bone graft composed from a patented nanocrystalline solution that stimulates the formation of healthy bone tissue after spinal fusion surgery.OssDsign Catalyst received market clearance from the Food and Drug Administration (FDA) in 2020 and was launched on the American market in august 2021. The addressable market for synthetic bone grafts after spinal fusion surgeries is valued at USD 2.6 billion and has a CAGR of approximately 7% during